Theralase Technologies (CVE:TLT) Shares Down 12.9% – Here’s Why

Shares of Theralase Technologies Inc. (CVE:TLT) fell 12.9% on Tuesday . The company traded as low as C$0.27 and last traded at C$0.27. 269,276 shares traded hands during trading, an increase of 122% from the average session volume of 121,028 shares. The stock had previously closed at C$0.31.

Theralase Technologies Stock Down 12.9 %

The business has a 50 day simple moving average of C$0.22 and a 200 day simple moving average of C$0.19. The company has a debt-to-equity ratio of 20.58, a current ratio of 1.21 and a quick ratio of 3.40. The stock has a market cap of C$66.30 million, a PE ratio of -13.50 and a beta of 1.36.

Theralase Technologies (CVE:TLT) last released its quarterly earnings results on Monday, August 12th. The company reported C($0.01) earnings per share (EPS) for the quarter. The firm had revenue of C$0.10 million during the quarter. On average, equities research analysts forecast that Theralase Technologies Inc. will post -0.05 EPS for the current fiscal year.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.